India to Lebanon: Apixaban Export Trade Route

To import Apixaban formulations into Lebanon, the following steps and requirements must be fulfilled:

2. Dossier Format: While the Common Technical Document (CTD) or electronic CTD (eCTD) formats are widely accepted internationally, specific requirements for Lebanon should be confirmed directly with the MoPH.

3. Approval Timelines: The Drug Registration Technical Committee (DRTC) is expected to review the drug's files within a maximum period of three months. Once the drug meets MoPH requirements, the DRTC sends the drug's samples to the Central Laboratory for testing. If approved, the file is then forwarded to the Pricing Committee to price it within one month.

5. GMP Inspection Requirements: The MoPH mandates GMP certification for all pharmaceutical products. For imported products, the GMP certificate issued by the competent regulatory authority of the country of origin is required.

Indian manufacturers exporting Apixaban formulations to Lebanon must comply with the following quality and GMP standards:

1. GMP Certification: Manufacturers must hold a valid GMP certificate issued by the competent regulatory authority of the country of origin.

2. Approved Facilities: The MoPH requires that the manufacturing facilities of imported pharmaceutical products comply with GMP standards.

3. Recent Inspections and Regulatory Actions: While specific recent inspections or regulatory actions by the MoPH against Indian pharmaceutical companies are not detailed in the available information, it is crucial for exporters to maintain compliance with all regulatory requirements to avoid potential issues.

In the past 18 months, several regulatory developments have impacted the importation of pharmaceutical products into Lebanon:

1. Implementation of the MediTrack System: Since 2020, the MoPH has implemented the "MediTrack" pharmaceutical traceability information system in all drugstores to track imported medications from the supplier's purchase to distribution. This system aims to enhance the monitoring and safety of pharmaceutical products within the Lebanese market.

2. Pharmacovigilance Inspections: The MoPH has established guidelines for pharmacovigilance inspections, emphasizing the importance of compliance with national laws and regulations. Inspection fees and related expenses may be applicable as per these guidelines.

Staying informed about these developments and ensuring compliance with all regulatory requirements is essential for the successful importation of Apixaban formulations into Lebanon.

Apixaban, an anticoagulant used to prevent and treat blood clots, has seen increasing demand in Lebanon due to a rising prevalence of cardiovascular diseases and an aging population. In 2024, Lebanon imported finished pharmaceutical formulations containing Apixaban valued at $75.1 million USD from India, accounting for 41.8% of India's total Apixaban formulation exports. This substantial import volume indicates a strong reliance on imported Apixaban formulations, with limited domestic manufacturing capacity for this specific medication.

Lebanon maintains a 0% MFN import duty rate for HS code 30049099, encompassing finished pharmaceutical formulations like those containing Apixaban. Additionally, under agreements such as the European Mediterranean Association Agreement and the Greater Arab Free Trade Area (GAFTA), goods from European and certain Arab countries are exempt from customs fees. However, these agreements do not currently extend to Indian pharmaceutical imports, which are still subject to the standard 0% duty rate. Lebanon does not impose anti-dumping duties on pharmaceutical imports, ensuring a favorable environment for international suppliers.

India is the predominant supplier of Apixaban formulations to Lebanon, with exports totaling $75.1 million USD in 2024. The primary Indian exporter is MACLEODS PHARMACEUTICALS LTD, contributing $74.8 million USD. The main Lebanese importer is ALGORITHM SAL, accounting for $74.6 million USD of these imports. While specific data on other supplying countries is limited, India's significant share underscores its competitive pricing and established trade relationships. Indian pharmaceutical manufacturers are known for offering cost-effective alternatives to European and Chinese counterparts, making them attractive partners for Lebanese distributors seeking affordable, high-quality medications.

India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. This extensive manufacturing capability extends to finished pharmaceutical formulations containing Apixaban, a widely used anticoagulant.

The country's manufacturing infrastructure includes 752 FDA-approved sites and 2,050 WHO-GMP certified plants as of 2024, the highest globally. This extensive network ensures that Indian manufacturers can produce high-quality Apixaban formulations that meet stringent international standards.

India's cost structure offers significant advantages in the production of finished dosage forms such as tablets and capsules. Factors contributing to this include lower labor costs, economies of scale, and a well-established supply chain for raw materials. These elements enable Indian manufacturers to offer Apixaban formulations at competitive prices without compromising on quality.

Several Indian pharmaceutical companies have received approvals from major regulatory bodies, including the FDA and WHO, for their facilities producing Apixaban formulations. For instance, Akums Drugs and Pharmaceuticals operates two units in Haridwar that have been granted European GMP certification, one of which produces solid oral dosage forms like tablets and hard gelatin capsules. Additionally, Alembic Pharmaceuticals has obtained multiple approvals from the FDA for generic medicines between 2024 and 2025. These certifications underscore the commitment of Indian manufacturers to maintaining high-quality standards in the production of Apixaban formulations.

When comparing Apixaban formulation exports from India, China, and the European Union (EU), several factors come into play, including cost, quality perception, regulatory acceptance in Lebanon, and supply reliability.

India's Apixaban formulations are known for their cost-effectiveness, primarily due to the country's efficient manufacturing processes and lower production costs. This makes Indian formulations more affordable compared to those from the EU, where higher labor and operational costs contribute to increased prices. China also offers competitive pricing; however, concerns regarding quality control and regulatory compliance have been raised in certain markets.

In terms of quality perception, Indian pharmaceutical companies have made significant investments to build systems, processes, capabilities, and culture that meet or exceed international standards. This commitment to quality has enhanced the global reputation of Indian pharmaceutical products. The EU is traditionally associated with high-quality pharmaceutical products, benefiting from stringent regulatory frameworks. While China has improved its manufacturing standards, some markets remain cautious due to past quality issues.

Regarding regulatory acceptance in Lebanon, Indian pharmaceutical products have a strong presence, with companies like MACLEODS PHARMACEUTICALS LTD being major exporters of Apixaban formulations to the Lebanese market. This indicates a favorable regulatory environment and established trust in Indian formulations. EU products are also well-accepted, while Chinese products may face more scrutiny due to varying regulatory standards.

Supply reliability is crucial for uninterrupted patient care. Indian manufacturers have demonstrated a robust supply chain with minimal disruptions, supported by a vast network of FDA and WHO-GMP certified facilities. The EU also maintains a reliable supply chain, though at higher costs. China's supply reliability has improved but can be affected by regulatory changes and geopolitical factors.

The India-Lebanon Apixaban formulation supply chain has proven to be reliable, supported by India's substantial manufacturing capacity and adherence to international quality standards.

Indian pharmaceutical companies have expanded their manufacturing capacities to meet global demand. For example, Granules India Limited's greenfield facility at Genome Valley, Hyderabad, received FDA approval in August 2025, adding an additional 10 billion doses of formulation capacity, a 40% increase over the existing capacity. This expansion enhances the ability to supply Apixaban formulations consistently.

Packaging and cold chain capabilities are critical for maintaining the integrity of pharmaceutical products. Indian manufacturers have invested in state-of-the-art facilities to ensure that Apixaban formulations are packaged and transported under optimal conditions, meeting international standards.

The regulatory compliance track record of Indian manufacturers is strong. Facilities such as those operated by Akums Drugs and Pharmaceuticals and Alembic Pharmaceuticals have received approvals from major regulatory bodies, including the FDA and WHO, indicating adherence to stringent quality standards.

There have been no significant supply disruptions reported in the India-Lebanon Apixaban formulation supply chain in recent years. Manufacturers continue to expand their capacities to meet growing demand, ensuring a stable supply.

For Lebanese buyers sourcing Apixaban formulations from India, the following strategic recommendations are advised:

• Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Apixaban formulations.

• Minimum Order Quantities (MOQs): Understand the MOQs set by Indian suppliers, which can vary based on production capacities and logistical considerations. Negotiating favorable MOQs can lead to cost savings and supply flexibility.

• Payment Terms: Familiarize yourself with common payment terms in India-Lebanon pharmaceutical trade, such as Letters of Credit (LC) or advance payments, to establish clear financial agreements and build trust with suppliers.

• Supplier Qualification Process: Implement a thorough qualification process, including audits of manufacturing facilities, verification of regulatory certifications (e.g., FDA, WHO-GMP), and assessment of quality control systems, to ensure compliance with international standards.

• Regulatory Compliance: Stay updated on both Indian and Lebanese regulatory requirements to ensure that imported Apixaban formulations meet all necessary standards and approvals, facilitating smooth market entry and distribution.

By adhering to these recommendations, Lebanese buyers can establish a robust and reliable supply chain for Apixaban formulations sourced from India.

By adhering to this comprehensive approach, Lebanese pharmaceutical companies can ensure that their Indian Apixaban suppliers meet the necessary quality and regulatory standards, thereby safeguarding product integrity and patient health.